Prelude Capital Management’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Prelude Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-290,000	Closed	-$2.44M	–	2021
2021 Q2	$2.44M	Buy	+290,000	New	+$3.07M	0.07%	234
2020 Q2	–	Sell	-3,400	Closed	-$31K	–	2249
2020 Q1	$31K	Sell	3,400 -42,100	-93%	-$431K	﹤0.01%	877
2019 Q4	$446K	Hold	45,500	–	–	0.02%	593
2019 Q3	$313K	Hold	45,500	–	–	0.01%	649
2019 Q2	$420K	Sell	45,500 -4,500	-9%	-$54.3K	0.02%	537
2019 Q1	$784K	Buy	+50,000	New	+$882K	0.04%	389

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Prelude Capital Management's TEVA Position: Q2 2026 in Review

Prelude Capital Management held its Teva Pharmaceutical Industries Limited (TEVA) position steady in Q2 2026 at 154,970 shares worth $5.25M. The position accounts for 0.38% of the portfolio, ranked #48.

Prelude Capital Management first reported a position in TEVA in Q2 2014 and has held it in 27 quarters since. 676 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Prelude Capital Management held 154,970 shares of Teva Pharmaceutical Industries Limited worth $5.25M as of Q2 2026.
Prelude Capital Management left its Teva Pharmaceutical Industries Limited share count unchanged in Q2 2026.
Teva Pharmaceutical Industries Limited made up 0.38% of Prelude Capital Management's portfolio in Q2 2026, its #48 holding.
Prelude Capital Management first reported a position in Teva Pharmaceutical Industries Limited in Q2 2014 and has held it in 27 quarters since.
676 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.